{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:22:25Z","timestamp":1787772145041,"version":"build-2784847793"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Esketamine is an innovative treatment for individuals with treatment-resistant depression (TRD). However, its adoption could depend on the perceptions and motivations of prescribing psychiatrists, among other factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aims to explore the attitudes of psychiatrists (of all levels, including those in training) across Saudi Arabia toward the use of esketamine for TRD and investigate the motivational factors related to their willingness to adopt it.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a cross-sectional study that utilized a convenience sampling method. The study tool consisted of a questionnaire developed by the research team and the Physician-Motivation Adoption Scale.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 223 participants surveyed, 19.73% reported having prescribed esketamine, most commonly to 1\u20132 patients. The most frequently perceived adverse effects were dissociation\/delusions\/hallucinations (66.82%), followed by dizziness\/vertigo (59.19%). Esketamine prescription was significantly associated with older age (p = 0.049), consultant-level practice (p = 0.003), practice in the Western Region (p &amp;lt; 0.001), lower concern about potential misuse (p = 0.027), perceiving easier access (p = 0.004), and fewer concerns about the administration process (p = 0.007). Ordinal logistic regression demonstrated that senior registrars, registrars, and residents were significantly less likely to prescribe esketamine than consultants (OR = 0.21, 0.17, and 0.10, respectively). \u201cNot being sure\u201d that cost was a barrier was associated with lower odds of prescribing (OR = 0.32, p = 0.022), whereas higher functional subscale scores were strongly associated with willingness to prescribe (OR = 1.62, p &amp;lt; 0.001). The most commonly reported barriers to prescribing esketamine included the administration process (66.37%) and cost (65.02%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite significant interest, actual adoption of esketamine is low, mainly due to logistical barriers, high costs, and availability issues. Concerns about side effects and potential misuse are also linked to hesitation. Accordingly, interventions to address the obstacles and concerns are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1726411","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T06:50:25Z","timestamp":1772175025000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Mental health professionals\u2019 perspective on the use of esketamine in treatment-resistant depression and their motivation to adopt it: a Saudi cross-sectional study"],"prefix":"10.3389","volume":"17","author":[{"given":"Ahmad H.","family":"Almadani","sequence":"first","affiliation":[{"name":"Department of Psychiatry, College of Medicine, King Saud University","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayedh H.","family":"Alghamdi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, College of Medicine, King Saud University","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gosay M.","family":"Almazyad","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, King Saud University Medical City, King Saud University","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleh I.","family":"Alfawaz","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, King Saud University Medical City, King Saud University","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed A.","family":"Ghaith","sequence":"additional","affiliation":[{"name":"Medical Department, Bupa CareConnect, Bupa Arabia","place":["Jeddah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali A.","family":"Alshehri","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, King Saud University Medical City, King Saud University","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed A.","family":"Aljaffer","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, College of Medicine, King Saud University","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleh A.","family":"Alghamdi","sequence":"additional","affiliation":[{"name":"Psychiatry Department, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU)","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"B1","unstructured":"Depression\n          \n          \n          \n          2023"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e442","DOI":"10.1371\/journal.pmed.0030442","article-title":"Projections of global mortality and burden of disease from 2002 to 2030","volume":"3","author":"Mathers","year":"2006","journal-title":"PloS Med"},{"key":"B3","volume-title":"Saudi National Mental Health Survey","author":"Altwaijri","year":"2020"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S29716","article-title":"Treatment-resistant depression: therapeutic trends, challenges, and future directions","volume":"6","author":"Al-Harbi","year":"2012","journal-title":"Patient Prefer Adherence"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2017.08.019","article-title":"Treatment resistant depression: a multi-scale, systems biology approach","volume":"84","author":"Akil","year":"2018","journal-title":"Neurosci Biobehav Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fneng.2010.00007","article-title":"Evolving refractory major depressive disorder paradigms","volume":"3","author":"Ward","year":"2010","journal-title":"Front Neuroeng"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report","volume":"163","author":"Rush","year":"2026","journal-title":"American Journal of Psychiatry"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and safety of fixed-dose esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: Results of a randomized, double-blind, active-controlled study (TRANSFORM-1)","volume":"22","author":"Fedgchin","year":"2019","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/2042098620937899","article-title":"Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review","volume":"11","author":"Salahudeen","year":"2020","journal-title":"Ther Adv Drug Saf"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2020.112629","article-title":"Ketamine as a mental health treatment: are acute psychoactive effects associated with outcomes? A systematic review","volume":"392","author":"Grabski","year":"2020","journal-title":"Behav Brain Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2023.2239045","article-title":"Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance","volume":"39","author":"Teeple","year":"2023","journal-title":"Curr Med Res Opin"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03149-z","article-title":"Real-world effectiveness and safety of esketamine nasal spray in patients with treatment-resistant depression: INTEGRATE study","volume":"42","author":"Molero","year":"2025","journal-title":"Adv Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyaf027","article-title":"Safety and efficacy with esketamine in treatment-resistant depression: Long-term extension study","volume":"28","author":"Zaki","year":"2025","journal-title":"Int J Neuropsychopharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20240655","article-title":"Real-world safety of esketamine nasal spray: A comprehensive analysis almost five years after first approval","volume":"182","author":"Sanacora","year":"2025","journal-title":"Am J Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e060967","DOI":"10.1136\/bmjopen-2022-060967","article-title":"Association of intranasal esketamine, a novel 'standard of care' treatment and outcomes in the management of patients with treatment-resistant depression: protocol of a prospective cohort observational study of naturalistic clinical practice","volume":"12","author":"Vazquez","year":"2022","journal-title":"BMJ Open"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1037\/pha0000650","article-title":"Changing the paradigm in treatment-resistant depression: a review of long-term efficacy and tolerability of esketamine nasal spray","volume":"31","author":"Herrera-Imbroda","year":"2023","journal-title":"Exp Clin Psychopharmacol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"20420986251347360","DOI":"10.1177\/20420986251347360","article-title":"Abuse liability for esketamine in a cohort of patients undergoing an acute treatment course to manage treatment-resistant depression: a secondary analysis of an observational study in real-world clinical practice","volume":"16","author":"Gutierrez","year":"2025","journal-title":"Ther Adv Drug Saf"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/15622975.2020.1836399","article-title":"Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: basic science, evidence-based knowledge and expert guidance","volume":"22","author":"Kasper","year":"2021","journal-title":"World J Biol Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2021.06.032","article-title":"Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review","volume":"293","author":"Ng","year":"2021","journal-title":"J Affect Disord"},{"key":"B20","doi-asserted-by":"publisher","first-page":"S401","DOI":"10.1016\/j.jval.2024.03.1876","article-title":"SA29 motivations and barriers for psychiatric practice adoption of esketamine nasal spray for treatment-resistant depression in the United States","volume":"27","author":"Brendle","year":"2024","journal-title":"Value Health"},{"key":"B21","volume-title":"Saudi Drug Information: Spravato (Esketamine hydrochloride)","year":""},{"key":"B22","unstructured":"Statistical yearbook 2021\n          \n          \n          Riyadh\n          Ministry of Health\n          \n          2022"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2021.09.014","article-title":"Comparison of long-term efficacy and safety of esketamine nasal spray plus oral antidepressant in younger versus older patients with treatment-resistant depression: post-hoc analysis of SUSTAIN-2, a long-term open-label phase 3 study","volume":"30","author":"Ochs-Ross","year":"2022","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2018.17060720","article-title":"Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide","volume":"175","author":"Canuso","year":"2018","journal-title":"Am J Psychiatry"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2018.3639","article-title":"Psychiatric practice patterns and barriers to the adoption of esketamine","volume":"76","author":"Wilkinson","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19020181","article-title":"A word to the wise about intranasal esketamine","volume":"176","author":"Schatzberg","year":"2019","journal-title":"Am J Psychiatry"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1177\/2045125319870039","article-title":"Esketamine nasal spray for treatment-resistant depression: clinical evidence and practical considerations","volume":"9","author":"Ross","year":"2019","journal-title":"Ther Adv Psychopharmacol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12891","article-title":"Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2)","volume":"81","author":"Wajs","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am J Psychiatry"},{"key":"B30","volume-title":"Esketamine (Spravato): risk evaluation and mitigation strategy and European public assessment report","year":"2019"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.12.002","article-title":"The PMA scale: a measure of physicians\u2019 motivation to adopt medical devices","volume":"20","author":"Hatz","year":"2017","journal-title":"Value Health"},{"key":"B32","doi-asserted-by":"crossref","first-page":"297","DOI":"10.20344\/amp.22815","article-title":"Attitudes and perceptions of Portuguese psychiatrists and psychologists on the clinical use of ketamine","volume":"38","author":"Mota","year":"2025","journal-title":"Acta Med Port"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e53987","DOI":"10.7759\/cureus.53987","article-title":"Exploring esketamine's therapeutic outcomes as an FDA-designated breakthrough for treatment-resistant depression and major depressive disorder with suicidal intent: a narrative review","volume":"16","author":"Kumari","year":"2024","journal-title":"Cureus"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.3739","article-title":"Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial","volume":"75","author":"Daly","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"Am J Psychiatry"},{"key":"B36","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial","volume":"76","author":"Daly","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1101\/2025.06.01.25328722","article-title":"Esketamine implementation challenges in psychiatry: a qualitative analysis of mental healthcare providers\u2019 social media commentary","author":"Barnett","year":"2025","journal-title":"medRxiv"},{"key":"B38","volume-title":"SPRAVATO\u00ae (esketamine) safety and tolerability","year":"2024"},{"key":"B39","unstructured":"Drug list \u2013 Spravato"},{"key":"B40","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11126-020-09871-x","article-title":"Adverse effects of esketamine for the treatment of major depression disorder: findings from randomized controlled trials","volume":"93","author":"Yang","year":"2022","journal-title":"Psychiatr Q"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1177\/20420986241310685","article-title":"Is there a risk of esketamine misuse in clinical practice","volume":"16","author":"Roncero","year":"2025","journal-title":"Ther Adv Drug Saf"},{"key":"B42","volume-title":"Saudi board psychiatry curriculum","year":"2022"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1177\/10398562231155125","article-title":"A survey of Australian psychiatrists\u2019 and psychiatry trainees\u2019 knowledge of and attitudes towards psychedelics in the treatment of psychiatric disorders","volume":"31","author":"Grover","year":"2023","journal-title":"Australas Psychiatry"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1726411\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T06:50:28Z","timestamp":1772175028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1726411\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":43,"alternative-id":["10.3389\/fpsyt.2026.1726411"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1726411","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"article-number":"1726411"}}